SRGN and prostate carcinoma: In previous studies, most researches found that high SRGN expression was correlated with low survival rate of most tumors such as breast cancer [33], prostate cancer [34], colorectal cancer [15], nasopharyngeal carcinoma [17], glioma [35], and primary lung adenocarcinomas [36].